Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

Overview of attention for article published in Clinical Cancer Research, December 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

So far, Altmetric has seen 4 news stories from 4 outlets.

Summary Day One Biopharmaceuticals is looking to file an NDA after successful glioma data.

Patients with recurrent or progressive BRAF V600E mutation–positive glioma experienced clinical activity following combination…

Dabrafenib plus trametinib produced clinically meaningful objective responses rates in patients with recurrent or progressive…

Glioma of the left parietal lobe. CT scan with contrast enhancement. Credit: Mikhail Kalinin/CC BY-SA 3.0 Dabrafenib (Tafinlar)…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.